|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:ageRange
|
18 Years and older
|
|
gptkbp:allocates
|
Randomized
|
|
gptkbp:clinicalTrialPhase
|
Phase 3
|
|
gptkbp:clinicalTrialsGovURL
|
https://clinicaltrials.gov/ct2/show/NCT02475681
|
|
gptkbp:completedIn
|
September 2021
|
|
gptkbp:conditionStudied
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:enrollment
|
1274
|
|
gptkbp:gender
|
All
|
|
gptkbp:intervention
|
gptkb:Placebo
gptkb:Pembrolizumab
|
|
gptkbp:location
|
International
|
|
gptkbp:mask
|
Double-blind
|
|
gptkbp:officialName
|
A Phase III Study of Pembrolizumab (MK-3475) as Maintenance Therapy in Subjects With Locally Advanced/Unresectable or Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Disease Has Not Progressed After First Line Platinum Based Chemotherapy
|
|
gptkbp:primaryCompletionDate
|
September 2021
|
|
gptkbp:result
|
Overall survival
Progression-free survival
|
|
gptkbp:sponsor
|
gptkb:Merck_Sharp_&_Dohme_LLC
|
|
gptkbp:startDate
|
June 2015
|
|
gptkbp:studyType
|
Interventional
|
|
gptkbp:bfsParent
|
gptkb:ELEVATE-TN
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
NCT02475681
|